Partnership Growth Forge Biologics is actively expanding its partner ecosystem through strategic collaborations with Restore Vision, Skylark Bio, Epicrispr Biotechnologies, Ascidian Therapeutics, and The Progeria Research Foundation. This indicates a strong openness to outsourcing development and manufacturing capabilities, presenting opportunities to propose complementary services or co-development arrangements.

AAV and cGMP Focus The company frequently engages in AAV development and cGMP manufacturing partnerships, signaling ongoing demand for scalable gene therapy production, process development, and quality-compliant manufacturing support across multiple programs.

Retinal Gene Therapy Recent collaborations center on retinal programs (Ascidian's ACDN-01 for Stargardt disease), suggesting a market opening for specialized ocular gene therapy capabilities, regulatory alignment, and supply chain readiness tailored to ophthalmology-focused initiatives.

Broad Therapeutic Reach Forge Biologics positions itself as a manufacturing and development hub for diverse gene therapy programs, from Progeria to retinal diseases, indicating cross-program capacity needs, portfolio diversification opportunities, and potential for platform-wide service upsell such as process development and regulatory consulting.

Financial and Scale Signals With substantial revenue and funding, plus a sizeable headcount in the mid-market range, Forge Biologics appears prepared to scale partnerships, invest in additional capacity, and pursue longer-term, multi-program engagements beyond single-project collaborations.